Treating disruptive behavior disorders with risperidone: A 1-year, open-label safety study in children and adolescents

Journal of Child and Adolescent Psychopharmacology

Volumn 18, Issue 4, 2008, Pages 337-345

  Haas, Magali ^a   Karcher, Keith ^a   Pandina, Gahan J ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIINFECTIVE AGENT; DEXAMPHETAMINE; IMIPRAMINE; METHYLPHENIDATE; NEUROLEPTIC AGENT; PLACEBO; RISPERIDONE;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ABNORMAL VISION; ADOLESCENT; ANXIETY; APPENDICITIS; ARTHRITIS; ARTICLE; BEHAVIOR DISORDER; BRONCHITIS; CHILD; CLINICAL TRIAL; CONTUSION; DEPRESSION; DISRUPTIVE BEHAVIOR; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FEVER; FLU LIKE SYNDROME; FRACTURE; GLUCOSE METABOLISM; HEADACHE; HUMAN; INJURY; INTELLIGENCE QUOTIENT; LACERATION; LIPID METABOLISM; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MENINGITIS; METABOLIC DISORDER; NAUSEA; NUTRITIONAL DISORDER; OPEN STUDY; OPPOSITIONAL DEFIANT DISORDER; PAPILLEDEMA; PHARYNGITIS; PNEUMONIA; PROLACTIN BLOOD LEVEL; RECURRENT DISEASE; RHINITIS; SIDE EFFECT; SOMNOLENCE; SPRAIN; SUICIDAL IDEATION; SUICIDE ATTEMPT; SYNCOPE; TARDIVE DYSKINESIA; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT GAIN;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; ATTENTION DEFICIT AND DISRUPTIVE BEHAVIOR DISORDERS; BASAL GANGLIA DISEASES; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INTELLIGENCE; LONGITUDINAL STUDIES; MALE; PROLACTIN; PSYCHOMETRICS; RISPERIDONE; TIME FACTORS; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 50849130259     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2007.0098     Document Type: Article

References (26)

1. Aman MG, Tassé MJ, Rojahn J, Hammer D: The Nisonger CBRF: A child behavior rating form for children with developmental disabilities. Res Dev Disabil 17:41-57, 1996.
2. Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL; Risperidone Disruptive Behavior Study Group: Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 159:1337-1346, 2002.
3. Aman MG, Binder C, Turgay A. Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ. J Child Adolesc Psychopharmacol 14:243-254, 2004.
4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV). Washington (DC): American Psychistric Association; 1994.
5. Anderson GM, Scahill L, McCracken JT, et al. Effects of short-and long-term risperidone treatment on prolactin levels in children with autism. Biol Psychiatry 2007;61:545-550.
6. Armenteros JL, Lewis JE and Davalos M: Risperidone augmentation for treatment-resistant aggression in Attention-Deficit/Hyperactivity Disorder: A placebo-controlled pilot study. J Am Acad Child Adolesc Psychiatry 46:558-565, 2007.
7. Correll CU, Carlson HE: Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry 45:771-791, 2006.
8. Croonenberghs J, Fegert JM, Findling RL, De Smedt G, Van Dongen S: Risperidone Disruptive Behavior Study Group: Risperidone in children with disruptive behavior disorders and subaverage intelligence: A 1-year, open-label study of 504 patients. J Am Acad Child Adolesc Psychiatry 44:64-72, 2005.
9. Desmangles JC, Lappe JM, Lipaczewski G, Haynatzki G: Accuracy of pubertal Tanner staging self-reporting. J Pediatr Endocrinol Metab 19:213-221, 2006.
10. Ezpeleta L, Keller G, Erkanli A, Costello EJ, Angold A: Epidemiology of psychiatric disability in childhood and adolescence. J Child Psychol Psychiatry 42:901-914, 2001.
11. Findling RL, Aman MG, Eerdekens M, Derivan A, Lyons B; Risperidone Disruptive Behavior Study Group: Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ. Am J Psychiatry 161:677-684, 2004.
12. Grumbach MM, Styne DM: Puberty: Ontogeny, neuroendocrinology, physiology and disorders. In: Williams Textbook of Endocrinology, 9th ed. Edited by Williams RH, Foster DW, Larsen PR, Kronenberg H, Wilson JD. Philadelphia, WB Saunders, 1998, pp 512-516.
13. Guy W: Clinical global impressions. In: ECDEU Assessment Manual for Psychopharmacology. Rockville, MD, National Institute of Mental Health, 1976, pp 217-222.
14. Jensen JB. Conduct disorder and other disruptive behaviours: Pediatric psychopharmacology. Curr Psychosis Ther Rep 2004;2:104-108.
15. Jensen P, Buitelaar J, Pandina G, Binder C, Haas M: Management of psychiatric disorders in children and adolescents with atypical antipsychotics. Eur Child Adolesc Psychiatry 16:104-120, 2007.
16. Kutcher S, Aman M, Brooks SJ, Buitelaar J, van Daalen E, Fegert J, Findling RL, Fisman S, Greenhill LL, Huss M, Kusumakar V, Pine D, Taylor E, Tyano S: International consensus statement on attention-deficit/hyperactivity disorder (ADHD) and disruptive behaviour disorders (DBDs): Clinical implications and treatment practice suggestions. Eur Neuropsychopharmacol 14:11-28, 2004.
17. Pandina G, Aman M, Findling R: Risperidone in the management of disruptive behavior disorders. J Child Adolesc Psychopharmacol 16:379-392, 2006.
18. Reyes M, Buitelaar J, Toren P, Augustyns I, Eerdekens M: A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. Am J Psychiatry 163:402-410, 2006a.
19. Reyes M, Croonenberghs J, Augustyns I, Eerdekens M: Long-term use of risperidone in children with disruptive behavior disorders and subaverage intelligence: Efficacy, safety, and tolerability. J Child Adolesc Psychopharmacol 16:260-272, 2006b.
20. Reyes M, Olah R, Csaba K, Augustyns I, Eerdekens M: Longterm safety and efficacy of risperidone in children with disruptive behaviour disorders. Results of a 2-year extension study. Eur Child Adolesc Psychiatry 15:97-104, 2006c.
21. Shaffer D, Gould MS, Brasic J, Ambrosini P, Fisher P, Bird H, Aluwahlia S: A children's global assessment scale (CGAS). Arch Gen Psychiatry 40:1228-1231, 1983.
22. Snyder R, Turgay A, Aman M, Binder C, Fisman S, Carroll A; Risperidone Conduct Study Group: Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry 41:1026-1036, 2002.
23. Staller J. The effect of long-term antipsychotic treatment on prolactin. J Child Adolesc Psychopharmacol 2006;317-326, 2006.
24. Tassé MJ, Aman MG, Hammer D, Rojahn J: The Nisonger Child Behavior Rating Form: Age and gender effects and norms. Res Dev Disabil 17:59-75, 1996.
25. Turgay A, Binder C, Snyder R, Fisman S: Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics 110:e34, 2002.
26. Van Goozen SM, Fairchild G. Neuroendocrine and neurotransmitter correlates in children with antisocial behavior. Horm Behav 2006;50:647-654.